Herpes simplex virus vaccines: perspectives;Vaccination antiherpès simplex virus : perspectives

Revue de Medecine Interne

Volumn 28, Issue 1, 2007, Pages 16-21

  Deback, C ^a   Huraux, J M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antiviral therapy; Clinical trial; Genital herpes; Herpes simplex virus; Immune defences; Immune escape; Latency; Vaccine

Indexed keywords

HERPES SIMPLEX VACCINE; IMIQUIMOD; RESIQUIMOD; SPERMICIDAL AGENT; VALACICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; GENE EXPRESSION; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MOUTH INFECTION; PANDEMIC; REINFECTION; SEROPREVALENCE; SHORT SURVEY; VACCINATION; VIRUS REPLICATION;

CLINICAL TRIALS, PHASE III; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HUMANS; SIMPLEXVIRUS;

EID: 33846035355     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.09.022     Document Type: Short Survey

References (22)

1. Huraux J.M., and Rozenberg F. Herpes simplex virus. In: Huraux J.M., Nicolas J.C., Agut H., and Peigue-Lafeuille H. (Eds). Traité de virologie médicale (2003), Éditions ESTEM, Paris 161-177
2. Malkin J.E., Morand P., Malvy D., Ly T.D., Chanzy B., de Labareyre C., et al. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sex. Transm. Infect. 78 (2002) 201-203
3. Malvy D., Halioua B., Lancon F., Rezvani A., Bertrais S., Chanzy B., et al. Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the HERPIMAX study. Sex. Transm. Dis. 32 (2005) 499-505
4. Huraux J.M. Généralités sur les Herpesviridae. In: Huraux J.M., Nicolas J.C., Agut H., and Peigue-Lafeuille H. (Eds). Traité de virologie médicale (2003), Éditions ESTEM, Paris 153-159
5. Flint S.J., Enquist L.W., Racaniello V.R., and Skalka A.M. Patterns of infection. Principles of virology. Molecular biology, pathogenesis, and control of animal viruses. 2nd edition (2004), ASM Press, Washington, DC 597-621
6. Flint S.J., Enquist L.W., Racaniello V.R., and Skalka A.M. Virus offense meets host defense. Principles of virology. Molecular biology, pathogenesis, and control of animal viruses. 2nd edition (2004), ASM Press, Washington, DC 531-594
7. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347 (2002) 1652-1661
8. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas Jr. J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomised controlled trials. Chiron HSV Vaccine Study Group. JAMA 282 (1999) 331-340
9. Whitley R.J., and Roizman B. Herpes simplex viruses: is a vaccine tenable?. J. Clin. Invest. 110 (2002) 145-151
10. Koelle D.M., and Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16 (2003) 96-113
11. Corey L. Strategies for interrupting the transmission of genital HSV infection. An IHMF management strategies Workshop, 25-26 September 2002 and ratified at the 10th annual meeting of the IHMF, Paris, 28 Feb-2 Mar 2003. Herpes 2004;11(Supplement 3):129A-87A www.ihmf.org.
12. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350 (2004) 11-20
13. Wald A., Langenberg A.G., Link K., Izu A.E., Ashley R., Warren T., et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 285 (2001) 3100-3106
14. Schacker T.W., Conant M., Thoming C., Stanczak T., Wang Z., and Smith M. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomised, double blind, placebo-controlled study. Antimicrob. Agents Chemother. 46 (2002) 3243-3248
15. Spruance S.L., Tyring S.K., Smith M.H., and Meng T.C. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis. 184 (2001) 196-200
16. Langenberg A. Interrupting herpes simplex virus type 2-transmission: the role of condoms and microbicides. Herpes 11 Suppl 3 (2004) 147A-154A
17. Keadle T.L., Laycock K.A., Morris J.L., Leib D.A., Morrison L.A., Pepose J.S., et al. Therapeutic vaccination with vhs(-) herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice. J. Gen. Virol. 83 (2002) 2361-2365
18. Spector F.C., Kern E.R., Palmer J., Kaiwar R., Cha T.A., Brown P., et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2-vaccine in guinea pigs. J. Infect. Dis. 177 (1998) 1143-1154
19. Parkinson R.J., Mian S., Bishop M.C., Gray T., Li G., McArdle S.E., et al. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy. Prostate 56 (2003) 65-73
20. de Bruyn G., Vargas-Cortez M., Warren T., Tyring S.K., Fife K.H., Lalezari J., et al. A randomised controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24 (2006) 914-920
21. Sin J., Kim J.J., Pachuk C., Satishchandran C., and Weiner D.B. ADN vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol. 74 (2000) 11173-11180
22. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism?. Clin. Diagn. Lab. Immunol. 11 (2004) 437-445